Diabetes Therapy

Complete response submitted to FDA for Symlin for glucose control

Published in Obesity and Diabetes Week, October 18th, 2004

Amylin Pharmaceuticals, Inc., (AMLN) announced the submission of a complete response to the U.S. Food and Drug Administration's (FDA) second approvable letter for Symlin (pramlintide acetate).

Resubmission of a complete response after receipt of an approvable letter is intended to answer all of the questions that need to be addressed prior to approval.

The FDA is expected to respond to this new submission within 6 months.

"Based on numerous discussions with the FDA, we believe that data generated since our last Symlin submission in June 2003 and additional analyses of earlier studies, including the pivotal studies, answer the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2004-10-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry